Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study
Purpose To compare the efficacy and safety of immune checkpoint inhibitors (ICIs) versus bevacizumab (both combined with chemotherapy) for first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC). Methods This single-center retrospective study enrolled 194 patients with driv...